Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.73 |
| ▸ | MAOB | P27338 | 5/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | SDHA | P31040 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CALML3 | P27482 | 1/20 | 0.73 |
| ▸ | F10 | P00742 | 9/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568910 | 1.00 | MAOA (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3568907 | 1.00 | MAOA (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6991163 | 0.92 | MAOA (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5738510 | 0.92 | MAOA (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3572288 | 0.91 | MAOA (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3572287 | 0.91 | MAOA (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6987354 | 0.90 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6987348 | 0.90 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3568166 | 0.89 | MAOA (0.82) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3185881 | 0.89 | MAOA (0.82) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| US-7405228-B2 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED (IN) | 2008-07-29 | — | — | US | disclosed |
| US-7405228-B2 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED (IN) | 2008-07-29 | — | — | US | disclosed |
| EP-1664038-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY | Wockhardt Limited (IN) | 2006-06-07 | — | — | EP | disclosed |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED | 2005-06-30 | — | — | US | disclosed |
| WO-2005054234-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED (IN) | 2005-06-16 | — | — | WO | disclosed |
| EP-0750618-B1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UPJOHN CO (US) | 2003-02-19 | — | — | EP | disclosed |
| US-5668286-A | ANTIBIOTIC | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | GMPS, MPO, ARG1 | MAOA 2638/4885MAOB 2975/4885PTGS1 170/4885 |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | GMPS, MPO, ARG1 | MAOA 2638/4885MAOB 2975/4885PTGS1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.